The Broad Institute of MIT and Harvard have expanded its strategic partnership with Bayer to launch the new Precision Cardiology Laboratory (PCL), which focuses on developing new therapeutics for heart failure.
To be situated at the institute, PCL will leverage new tools and approaches to gain more insights into the various causes of heart failure and treating them.
Researchers from both organisations will jointly work at the new facility, combining the institute’s basic scientific discovery innovation and clinical expertise with Bayer’s extensive drug development experience.
The laboratory initially plans to develop high-resolution, single-cell maps of cardiovascular tissues in both animal and human models.
The scientists will use tissue samples from healthy people, as well as cardiovascular disease to build datasets aimed at gaining a better understanding of heart failure.
Bayer Pharmaceuticals executive committee member and R&D head Joerg Moeller said: “The Broad Institute is an important and strategic partner for Bayer, enabling us to deepen our understanding in the area of cardiovascular diseases and we are looking forward to extending our collaboration further.
How well do you really know you competitors?
Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“Joint laboratories are a novel partnering model for industry and academia and are bringing both Bayer and Broad cardiovascular research to the next level.”
Bayer and the Broad Institute first forged an alliance in 2013 for an oncology programme. This was later extended in 2015 to include a cardiovascular-specific project using genomics to better understand heart disease.
The new PCL will utilise non-genomic approaches to accelerate new drug targets for heart failure. As part of the now expanded collaboration, Bayer will invest $22m over the next five years.
Findings from the partnership will be openly shared via publicly available datasets and academic journals.